Xbrane Biopharma AB (publ) publishes shareholder letter

Shareholder letter
2016-08-02
  
Xbrane Biopharma publishes shareholder letter which from today will be available on the company's website: http://xbrane.com/investors/shareholder-letter/

The shareholder letter is aimed to further strengthen the company's communications towards existing shareholders and the stock market with focus on information about the company's development. The shareholder letter will be published twice a year as a supplement to the company's existing communications towards the stock market. 

About Xbrane Biopharma
Xbrane is a commercial phase Swedish biopharmaceutical company specialized in High Demand Complex Generics. Xbrane has world leading expertise in developing generics for injectable controlled release drugs and proprietary high-yield protein expression technology for the development of biosimilars. The goal is to become a global leader within the company's portfolio of High Demand Complex Generics. Xbranes's headquarter is located in Stockholm and the company's in-house research and development facilities are in Sweden and Italy. Xbrane is listed at Nasdaq First North since February 3rd under the name XBRANE and Avanza Bank AB is Xbranes certified advisor. For more information see www.xbrane.com.

For further information, please contact:
Martin Åmark
Chief Executive Officer
M: +46 (0) 763-093 777
E: martin.amark@xbrane.com